Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer - The ASCO Post
Cancer Trial Results
Lynparza® for the Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Adenocarcinoma of the Pancreas
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer - YouTube
ASCO GI 2021: Results From the Phase 3 POLO Trial
ASCO GI 2021: Results From the Phase 3 POLO Trial
Cancer Trial Results
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Pancreatic cancer treatment: Polo trial for Maintenance Lynparza (olaparib)
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Cancer Trial Results
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
Phase III POLO Trial - Slideset Download - Clin Onc June 2019 | CCO
